News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,650 Results
Type
Article (52401)
Company Profile (300)
Press Release (647936)
Multimedia
Podcasts (223)
Webinars (26)
Section
Business (214534)
Career Advice (2844)
Deals (34167)
Drug Delivery (227)
Drug Development (80940)
Employer Resources (181)
FDA (16362)
Job Trends (15021)
News (324448)
Policy (31558)
Tag
2025 Best Places to Work (19)
2026 Best Places to Work (26)
2027 BioCapital Standard (3)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (6)
2027 NextGen (4)
2027 Pharm Country Standard (5)
40 Under 40 (4)
Academia (2969)
Academic (1)
Accelerated approval (75)
ADA (53)
Adcomms (43)
Allergies (228)
Alliances (46518)
ALS (287)
Alzheimer's disease (2116)
Antibody-drug conjugate (ADC) (759)
Approvals (16978)
Artificial intelligence (997)
ASCO (338)
Autoimmune disease (524)
Automation (75)
Bankruptcy (344)
Belgium (44)
Best Places to Work (11754)
BIO (77)
Biologics (119)
BIOSECURE Act (23)
Biosimilars (299)
BioSpace Insights (191)
Biotechnology (211)
Bispecific (60)
Bladder cancer (247)
Brain cancer (99)
Breast cancer (957)
Cancer (7875)
Cardiovascular disease (667)
Career advice (2449)
Career pathing (64)
CAR-T (459)
CDC (79)
CDMO (231)
Celiac Disease (6)
Cell-line development (1)
Cell therapy (1210)
Cervical cancer (66)
Clinical research (72233)
Collaboration (2767)
Commercialization (72)
Company closure (9)
Compensation (1862)
Complete response letters (120)
COVID-19 (3006)
CRISPR (152)
CRO (6)
C-suite (1707)
Cystic fibrosis (182)
Data (11017)
Decentralized trials (4)
Denatured (68)
Depression (222)
Dermatology (205)
Diabetes (817)
Diagnostics (7217)
Digital health (72)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (502)
Drug pricing (242)
Drug shortages (40)
Duchenne muscular dystrophy (382)
Earnings (74346)
Editorial (84)
Employer branding (24)
Employer resources (169)
ESMO (433)
Events (105077)
Executive appointments (1382)
Eye disease (25)
FDA (21321)
Fibrodysplasia Ossificans Progressiva (17)
Fragile X (6)
Friedreich's ataxia (29)
Frontotemporal dementia (43)
Funding (2288)
Gene editing (315)
Generative AI (90)
Gene therapy (956)
GLP-1 (1362)
Government (5125)
Grass and pollen (6)
Guidances (441)
Healthcare (19702)
Hematology (230)
HIV (127)
Huntington's disease (93)
Idiopathic pulmonary fibrosis (15)
IgA nephropathy (155)
Immunology and inflammation (414)
Immuno-oncology (160)
Indications (298)
Infectious disease (3450)
Inflammatory bowel disease (281)
Inflation Reduction Act (17)
Influenza (163)
Intellectual property (388)
Interviews (533)
IPO (16450)
IRA (58)
Job creations (3516)
Job search strategy (1990)
JPM (72)
Kidney cancer (32)
Kidney disease (177)
Labor market (126)
Layoffs (705)
Leadership (69)
Legal (6884)
Licensing (129)
Liver cancer (119)
Longevity (53)
Lung cancer (1089)
Lung diease (26)
Lymphoma (560)
Machine learning (74)
Management (67)
Manufacturing (1570)
Marketing (40)
MASH (254)
Medical affairs (5)
Medical device (13628)
Medtech (13917)
Mergers & acquisitions (19284)
Metabolic disorders (2097)
Middle East (2)
mRNA (336)
Multiple sclerosis (260)
Multispecific (6)
NASH (24)
Netherlands (38)
Neurodegenerative disease (625)
Neuropsychiatric disorders (150)
Neuroscience (4286)
Neurotech (3)
NextGen: Class of 2026 (6922)
Non-profit (4713)
Now hiring (82)
Obesity (996)
Opinion (396)
Ovarian cancer (296)
Pain (348)
Pancreatic cancer (453)
Parkinson's disease (491)
Partnered (44)
Patents (789)
Patient advocacy (8)
Patient recruitment (963)
Patient selection (117)
Peanut (79)
People (64681)
Peptides (45)
Pharmaceutical (43)
Pharmacy benefit managers (41)
Phase 1 (22506)
Phase 2 (31898)
Phase 3 (24003)
Pipeline (14434)
Policy (417)
Postmarket research (2338)
Preclinical (9569)
Press Release (72)
Prostate cancer (401)
Psychedelics (103)
Radioligand (3)
Radiopharmaceuticals (442)
Rare diseases (1584)
Real estate (5561)
Recruiting (78)
Regenerative medicine (37)
Regulatory (27000)
Reports (67)
Research institute (2673)
Resumes & cover letters (444)
Rett syndrome (60)
RNA editing (39)
RSV (102)
Saudi Arabia (1)
Schizophrenia (230)
Series A (397)
Series B (281)
Service/supplier (3)
Sickle cell disease (150)
Special edition (36)
Spinal muscular atrophy (193)
Sponsored (57)
Startups (3622)
State (2)
Stem cells (8)
Stomach cancer (23)
Substance use disorders (23)
Supply chain (162)
Switzerland (24)
Tariffs (100)
Tax incentives (1)
The Weekly (152)
Vaccines (1400)
Venture capital (179)
Weight loss (661)
Wet AMD (6)
Women's health (179)
Women in leadership (2)
Worklife (28)
Date
Today (216)
Last 7 days (894)
Last 30 days (3734)
Last 365 days (31483)
2026 (28509)
2025 (30470)
2024 (35268)
2023 (39803)
2022 (50985)
2021 (55369)
2020 (54203)
2019 (47417)
2018 (35857)
2017 (32942)
2016 (31641)
2015 (36605)
2014 (28125)
2013 (22988)
2012 (24177)
2011 (24795)
2010 (21890)
Location
Africa (908)
Alabama (117)
Alaska (7)
Arizona (378)
Arkansas (15)
Asia (42333)
Australia (7387)
California (16146)
Canada (4564)
China (2017)
Colorado (714)
Connecticut (713)
Delaware (530)
Europe (97828)
Florida (2471)
Georgia (526)
Hawaii (4)
Idaho (63)
Illinois (1311)
India (144)
Indiana (738)
Iowa (35)
Japan (764)
Kansas (151)
Kentucky (57)
Louisiana (62)
Maine (74)
Maryland (1856)
Massachusetts (11770)
Michigan (401)
Minnesota (849)
Mississippi (7)
Missouri (167)
Montana (37)
Nebraska (27)
Nevada (196)
New Hampshire (84)
New Jersey (4343)
New Mexico (34)
New York (4254)
North Carolina (2039)
North Dakota (14)
Northern California (8244)
Ohio (480)
Oklahoma (28)
Oregon (48)
Pennsylvania (3117)
Puerto Rico (38)
Rhode Island (60)
South America (1207)
South Carolina (104)
South Dakota (2)
Southern California (6547)
Tennessee (266)
Texas (2698)
United States (57081)
Utah (477)
Vermont (2)
Virginia (408)
Washington D.C. (79)
Washington State (1282)
West Virginia (4)
Wisconsin (181)
Wyoming (6)
700,650 Results for "chiesi usa formerly known as cornerstone therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chiesi Group appoints Paolo Paoletti to its Board of Directors
October 29, 2026
·
3 min read
Press Releases
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth
September 15, 2026
·
3 min read
Press Releases
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
November 1, 2026
·
12 min read
Press Releases
Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington’s Disease Franchise
October 14, 2026
·
6 min read
Press Releases
Nanoscope Therapeutics to Participate in Advanced Therapies USA 2026 in Boston
October 29, 2026
·
7 min read
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.
April 29, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated
September 3, 2026
·
7 min read
Press Releases
Chiesi Global Rare Diseases Supports Continued Generation of Real-World and Scientific Evidence in Epidermolysis Bullosa (EB), Including New Data Presented at 2026 PeDRA Annual Conference
October 15, 2026
·
10 min read
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.
July 27, 2026
·
3 min read
·
Gabrielle Masson
Press Releases
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
June 11, 2026
·
8 min read
1 of 70,065
Next